Treatment of neuroblastoma with [125I]metaiodobenzylguanidine. |
| |
| Authors: | J C Sisson B Shapiro R J Hutchinson K R Zasadny S Mallette E E Mudgett D M Wieland |
| |
| Affiliation: | Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0028. |
| |
| Abstract: | To find a treatment that may be effective against micrometastases of advanced, stage III or IV neuroblastoma, [125I]metaiodobenzylguanidine (125I-MIBG) was used in a phase I toxicity trial. In seven patients, thrombocytopenia was encountered with absorbed whole body doses of 85-135 rad from 125I-MIBG, but the dosimetry was imprecise in predicting bone marrow injury. Three patients survived for over one year, results that may indicate efficacy of 125I-MIBG therapy. |
| |
| Keywords: | |
|
|
